CalciMedica, Inc. CALC
At closeNov 5, 2026, 4:00 AM EST
Pre-market · Nov 5, 4:00 AM ET
- YTD
- -95.92%
- 1 year
- -91.18%
- Market cap
- 9.18M
- EPS (ttm)
- -6.85
- Shares out
- 13.48M
- Forward P/E
- -1.69
- YTD return
- -95.92%
- 1-year return
- -91.18%
- Volume
- 43.70K
- Avg volume
- 81.75K
- Open
- 1.44
- Previous close
- 1.47
- Day's range
- 1.33 – 1.43
- 52-week range
- 1.00 – 36.00
- Price target
- 17.00 (+1163.9%)
- Earnings date
- Aug 12, 2024
1D +0.04 (+2.72%)
Key statistics
- Enterprise value
- 17.09M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.95
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -12.45M
- Total cash
- 19.14M
- Total debt
- 0
- Return on equity
- -83.76%
- Short % of float
- 1.25%
- 50-day average
- 3.46
- 200-day average
- 4.33
Analyst view
- Target (low)
- 15.00
- Target (mean)
- 17.00
- Target (high)
- 20.00
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.61 | -0.50 | +0.11 | +18.03% |
| Aug 12, 2024 | Jun 1, 2024 | -0.55 | -0.52 | +0.03 | +5.45% |
| Aug 12, 2024 | Jun 1, 2024 | -0.55 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.50 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.50 | -0.43 | +0.07 | +14.00% |
| Mar 28, 2024 | Dec 1, 2023 | -1.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | LUCID CAPITAL MARKETS | init | — | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 4, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 10, 2024 | Oppenheimer | main | Outperform | Outperform |
| Jul 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- calcimedica.com
News
CalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket 
12 Health Care Stocks Moving In Friday's After-Market Session - 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
CalciMedica Announces Stephen Bardin To Resign As CFO Effective After Q3 2026 10-Q Filing - 12 Health Care Stocks Moving In Thursday's After-Market Session
Your note
Sign in to keep a note on CALC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BJERKHOLT ERIC H | Director | Purchase | May 30, 2023 | 3,684 |
| DUNN MICHAEL JOHN | President | Conversion of Exercise of derivative security | Sep 8, 2024 | 11,761 |
| HEBBAR SUDARSHAN | Officer | Purchase | Nov 2, 2023 | 46,000 |
| LEHENY A RACHEL | Chief Executive Officer | Purchase | Oct 31, 2024 | 871,252 |
| MIDDLETON FRED A | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 5, 2024 | 2,451,860 |
| ROBERTS ERIC W | Officer, Director and Beneficial Owner | Purchase | Oct 31, 2024 | 974,810 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 17.66% | 1,000,000 | 2.76M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 13.85% | 783,904 | 2.16M | Sep 29, 2024 |
| Aisling Capital Management LP | 9.20% | 521,114 | 1.44M | Sep 29, 2024 |
| Vanguard Group Inc | 4.49% | 254,148 | 701.45K | Sep 29, 2024 |
| BML Capital Management, LLC | 2.72% | 153,887 | 424.73K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.18% | 66,553 | 183.69K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.99% | 226,183 | 624.26K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.59% | 33,310 | 91.94K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.49% | 27,965 | 77.18K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.26% | 14,545 | 40.14K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.21% | 11,756 | 32.45K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 8,038 | 22.18K | Oct 30, 2024 |